Siltuximab

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 297 publications

Serum proteomics reveals distinct phenotypic signatures to IL-6 blockade between two immunotherapies.

Serum proteomics reveals distinct phenotypic signatures to IL-6 blockade between two immunotherapies.

Journal: bioRxiv : the preprint server for biology

Published: April 10, 2026

Early intervention for high-risk smoldering multiple myeloma (SMM).

Early intervention for high-risk smoldering multiple myeloma (SMM).

Journal: The Cochrane database of systematic reviews

Published: March 18, 2026

Correction: Siltuximab as a first-line therapy for idiopathic multicentric Castleman disease: a retrospective analysis based on the SiMuLa study of the Italian regional network.

Correction: Siltuximab as a first-line therapy for idiopathic multicentric Castleman disease: a retrospective analysis based on the SiMuLa study of the Italian regional network.

Journal: Frontiers in oncology

Published: February 16, 2026

Case Report: Endothelial-targeted bridging therapy for a TTP-like phenotype in fulminant iMCD-TAFRO.

Case Report: Endothelial-targeted bridging therapy for a TTP-like phenotype in fulminant iMCD-TAFRO.

Journal: Frontiers in immunology

Published: December 27, 2025

Siltuximab as a first-line therapy for idiopathic multicentric Castleman disease: a retrospective analysis based on the SiMuLa study of the Italian regional network.

Siltuximab as a first-line therapy for idiopathic multicentric Castleman disease: a retrospective analysis based on the SiMuLa study of the Italian regional network.

Journal: Frontiers in oncology

Published: December 07, 2025

Primary adrenal insufficiency and autoimmune thyroiditis in an adolescent with Castleman-TAFRO syndrome.

Primary adrenal insufficiency and autoimmune thyroiditis in an adolescent with Castleman-TAFRO syndrome.

Journal: JCEM case reports

Published: November 20, 2025

Case Report: Targeted interleukin-6 blockade by siltuximab for cytokine release syndrome control and infection limitation in thirteen patients treated with bi-specific T-cell engagers.

Case Report: Targeted interleukin-6 blockade by siltuximab for cytokine release syndrome control and infection limitation in thirteen patients treated with bi-specific T-cell engagers.

Journal: Frontiers in immunology

Published: November 18, 2025

Comparative Safety of Tocilizumab and Siltuximab in Castleman Disease: Pharmacovigilance Study.

Comparative Safety of Tocilizumab and Siltuximab in Castleman Disease: Pharmacovigilance Study.

Journal: American journal of hematology

Published: September 12, 2025

Glycan-based biological degraders targeting the cytokine immune axis.

Glycan-based biological degraders targeting the cytokine immune axis.

Journal: Communications biology

Published: August 12, 2025

Snapshot Look at Castleman Disease.

Snapshot Look at Castleman Disease.

Journal: Journal of cellular and molecular medicine

Published: August 11, 2025

Striking effectiveness of siltuximab-based treatment in refractory idiopathic multicentric Castleman disease resembling IgG4-related disease.

Striking effectiveness of siltuximab-based treatment in refractory idiopathic multicentric Castleman disease resembling IgG4-related disease.

Journal: Journal of chemotherapy (Florence, Italy)

Published: August 06, 2025

Treatment of Idiopathic Multicentric Castleman's Disease With Sequential Thalidomide-Cyclophosphamide-Prednisone After Siltuximab:Report of One Case.

Treatment of Idiopathic Multicentric Castleman's Disease With Sequential Thalidomide-Cyclophosphamide-Prednisone After Siltuximab:Report of One Case.

Journal: Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae

Published: July 24, 2025

Showing 1-12 of 297

Last Updated: 04/28/2026